-
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
July 13, 2026 20:35 ET | Source: Mesoblast Limited NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L…
-
Guwahati Gets a Life-Saving Heart Breakthrough: Apollo Hospitals Performs Northeast India’s First LAA Closure
Recognised as one of the Best Cardiology Hospitals in Guwahati, Apollo’s expert team brings new hope to patients who cannot safely take blood-thinning medicines GUWAHATI, India, July 9, 2026 /PRNewswire/ — A silent but life-saving battle was won recently in Guwahati. Doctors at Apollo Hospitals Guwahati – widely regarded as the Best Hospital in Guwahati for…
-
Medkart Champions Generic Drug Quality Amid Rising Consumer Concerns
Ahmedabad, Gujarat, India With growing scrutiny around the quality and reliability of generic medicines in India, Medkart, Gujarat’s largest generic-first pharmacy chain, is stepping forward to assure patients that affordability does not mean compromise. In response to increasing consumer concerns, the company has reinforced its Medkart Assured program—rooted in audit-based sourcing, Schedule M compliance, and…
-
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 June 07, 2026 19:30 ET | Source: LENZ Therapeutics, Inc. SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine…
-
MrMed Expands Its Reach with New Bengaluru Cold-Chain Hub to Improve Access to GLP-1 and Critical Care Medicines
MrMed, India’s largest online super-specialty pharmacy, has opened a state-of-the-art cold-chain distribution hub in Bengaluru. The new facility strengthens the company’s ability to deliver temperature-sensitive medicines especially GLP-1 therapies quickly and safely across South India. MrMed Bengaluru Hub As diabetes and obesity continue to rise at an alarming rate, with over 100 million people in…
-
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
REYKJAVIK, Iceland, June 4, 2026 – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the resubmission to the U.S. Food and Drug Administration (FDA) of Biologics License Applications (BLAs) for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab), and AVT06,…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.